Highlights Landos Biopharma, Inc.

Equities

LABP

US5150692011

Delayed Nasdaq Other stock markets 11:40:16 2024-05-09 am EDT			5-day change	1st Jan Change
22.13 ^USD	-0.34%		-0.54%	+504.64%

Apr. 02	North American Morning Briefing : Stocks Seen -2-	DJ
Apr. 01	HC Wainwright Downgrades Landos Biopharma to Neutral From Buy	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Deals of the day-Mergers and acquisitions	Mar. 25	RE
Sector Update: Health Care Stocks Decline Late Afternoon	Mar. 25	MT
Top Midday Gainers	Mar. 25	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	Mar. 25	MT
AbbVie to Acquire Landos Biopharma For About $137.5 Million; Landos Shares Jump	Mar. 25	MT
Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie	Mar. 25	DJ
AbbVie in Deal to Acquire Landos Biopharma for $137.5 Million	Mar. 25	DJ
AbbVie to Acquire Landos Biopharma for About $137.5 Million	Mar. 25	MT
AbbVie to Acquire Landos Biopharma for About $137.5 Million	Mar. 25	MT
AbbVie to buy Landos to expand pipeline of immunity-related illnesses	Mar. 25	RE
AbbVie Inc. agreed to acquire Landos Biopharma, Inc. on March 24, 2024.	Mar. 24	CI
Landos Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Landos Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Landos Biopharma, Inc. Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn?s and Colitis	Nov. 21	CI
Landos Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Landos Biopharma to Present At the American College of Gastroenterology 2023 Annual Scientific Meeting	23-10-23	CI
Landos Biopharma Enters Research Collaboration to Investigate Effects of NX-13 on Epithelial Cells	23-09-14	MT
Landos Biopharma, Inc. Announces Strategic Research Collaboration with Ku Leuven and University Hospitals Leuven to Further Characterize the Effects of Nx-13 on Epithelial Cells	23-09-14	CI
Landos Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Landos Biopharma, Inc.

Equities

LABP

US5150692011

Highlights

Filters